Journal article
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Abstract
Purpose Provide evidence-based recommendations updating the 2015 ASCO guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC). Methods The ASCO NSCLC Expert Panel made recommendations based on a systematic review of randomized controlled trials from February 2014 to December 2016 plus the Cancer Care Ontario Program in Evidence-Based Care's update of a previous ASCO search. Results This guideline update …
Authors
Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB
Journal
Journal of Clinical Oncology, Vol. 35, No. 30,
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
October 20, 2017
DOI
10.1200/jco.2017.74.6065
ISSN
0732-183X
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
American Medical AssociationAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsB7-H1 AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellEvidence-Based MedicineGene Expression Regulation, NeoplasticHumansLung NeoplasmsMedical OncologyMolecular Targeted TherapyNeoplasm StagingNivolumabPractice Guidelines as TopicRandomized Controlled Trials as TopicSocieties, MedicalUnited States